Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate Kcentra
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Apixaban is an anticoagulant (also known as blood thinner) approved by the Food and Drug
Administration (FDA) for reducing the risk of stroke and systemic embolism in patients with
non-valvular atrial fibrillation. It has no reliable method of reversal. Kcentra is an FDA
approved drug derived from blood that is used as an antidote to treat people with bleeding
associated with taking the well-known anticoagulant warfarin. This is a Phase I,
placebo-controlled, single site, open-label, crossover trial to evaluate the reversibility
apixaban anticoagulation with Kcentra.